Topiramate
- PDF / 169,124 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 41 Downloads / 145 Views
1 S
Nephrolithiasis: case report In a multicenter, randomized, open-label prospective study (FORWARD) conducted from August 2014 to September 2017, involving 282 patients (aged 18–65 years), an adult patient [age and sex not stated] was described, who developed nephrolithiasis during treatment with topiramate [Topamax]. The patient, who had been diagnosed with chronic migraine, started receiving oral topiramate 25 mg/day immediate-release formulation. The patient was instructed to sequentially escalate the topiramate dose by 25 mg/day weekly. Subsequently, the patient developed nephrolithiasis [duration of treatment to reaction onset and outcome not stated]. Rothrock JF, et al. FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic 803497271 Migraine. Headache 59: 1700-1713, No. 10, Nov-Dec 2019. Available from: URL: http://doi.org/10.1111/head.13653
0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 22 Aug 2020 No. 1818
Data Loading...
